this commentary challenges the paradigm that the cytokinesis-block micronucleus assay (CBmn assay) with cultured human lymphocytes, as it is performed currently, is a sensitive and useful tool for detecting genotoxic effects in populations exposed occupationally or environmentally to genotoxic chemicals. Based on the principle of the assay and the available data, increased micronucleus (mn) frequencies in binucleated cells (BnC) are mainly due to mn produced in vitro during the cultivation period (i.e. mn produced in vivo do not substantially contribute to the mn frequency measured in BnC). the sensitivity of the assay for the detection of induced mn in BnC after an in vivo exposure to a genotoxic chemical is limited because cytochalasin B (Cyt-B) is added relatively late during the culture period and, therefore, the BnC that are scored do not always represent cells that have completed one cell cycle only. Furthermore, this delay means that damaged cells can be eliminated by apoptosis and/or that Dna damage induced in vivo can be repaired prior to the production of a mn in the presence of Cyt-B. a comparison with the in vitro CBmn assay used for genotoxicity testing leads to the conclusion that it is highly unlikely that Dna damage induced in vivo is the cause for increased mn frequencies in BnC after occupational or environmental exposure to genotoxic chemicals. this commentary casts doubt on the usefulness of the CBmn assay as an indicator of genotoxicity in human biomonitoring and questions the relevance of many published data for hazard identification and risk assessment. thus, it seems worthwhile to reconsider the use of the CBmn assay as presently conducted for the detection of genotoxic exposure in human biomonitoring.
Introduction
The cytokinesis-block micronucleus assay (CBMN assay) is the preferred method in human biomonitoring studies to detect cytogenetic effects after exposure to genotoxic agents. In this assay, micronuclei (MN) are scored in binucleated cells (BNC) after blocking cytokinesis with cytochalasin B (Cyt-B). The addition of Cyt-B allows for the selective analysis of MN in cells that have completed one mitosis in the presence of Cyt-B (1, 2) . Over time, the CBMN assay has evolved into a comprehensive so-called 'cytokinesis-block micronucleus cytome assay' (CBMN Cyt assay). In addition to scoring MN as a measure of chromosome breakage and chromosome loss, the assay is used to detect nucleoplasmatic bridges, a biomarker of DNA misrepair and/or telomere end-fusions, and nuclear buds, a biomarker of elimination of amplified DNA and/or DNA repair complexes. Information regarding the mechanisms leading to the formation of MN, nucleoplasmatic bridges and nuclear buds is obtained using fluorescence in-situ hybridisation (FISH) and molecular probes for centromeres and telomeres. The nuclear division index (NDI) or the CBPI is used to measure cytostatic effects and cytotoxicity is determined via apoptotic and/or necrotic cell ratios (1) . The CBMN assay or CBMN Cyt assay is used not only in the biomonitoring of human populations potentially exposed to mutagens but has manifold other applications. The assay is used in human studies as an indicator of mutagen and radiation sensitivity, a biological dosimeter of ionising radiation exposure, a measure of DNA-repair capacity and genomic stability (also in the context of various diseases) and a predictor of cancer susceptibility/risk. Many recent MN studies have been published in the context of nutrigenomics and pharmacogenomics. Besides its use in human studies, the CBMN assay with human lymphocytes is regularly used as an in vitro test in genotoxicity testing. A good overview about applications, recent advances and developments is provided in a special issue of Mutagenesis (3) .
The CBMN assay has been frequently used in the biomonitoring of populations potentially exposed occupationally or environmentally to genotoxic chemicals, and this commentary focuses on this use only. A review published in 2005 indicated that organic chemicals (with 21% of all studies) led the list of exposures investigated (4) . The most frequently evaluated compounds were styrene, polycyclic aromatic hydrocarbons, benzene, ethylene oxide and formaldehyde. Furthermore, many articles have been published on pesticides and inorganic chemicals/metal compounds. Typically, conflicting results are reported for the same type of exposure. However, the number of positive findings in independent studies for a particular exposure seems to provide sufficient confidence that exposure actually led to the cytogenetic effects in peripheral blood lymphocytes. Positive results obtained after relatively low environmental or workplace exposures are taken as an argument for the sensitivity of the assay. However, a recently published in vitro study suggested that the standard protocol of the CBMN assay is too insensitive to detect DNA damage induced by occupational and environmental exposure to genotoxic chemicals (5) . This publication stimulated a scientific dispute about the sensitivity of the CBMN assay in human biomonitoring and the relevance of the published in vitro data (6, 7) . Despite the established role of the CBMN assay in human biomonitoring, there seems to be need for a broader discussion of the drawbacks and the opportunities of this approach. This commentary is an attempt to critically assess the CBMN assay and the protocol commonly used in G. Speit human biomonitoring. Based on this analysis, it challenges the paradigm that the CBMN assay is suited to detect DNA damage in populations exposed occupationally and environmentally to genotoxic chemicals. mn in BnC are mainly produced in vitro in proliferating lymphocytes and mn produced in vivo do not substantially contribute to mn frequencies in BnC A standard protocol for the CBMN assay in human biomonitoring has been proposed by an international panel of experts (8) . This protocol has been accepted by the international scientific community and is commonly used (sometimes with minor modifications) in published studies. Lymphocyte cultures using whole blood or isolated lymphocytes are started by stimulation and transformation of T lymphocytes with phytohaemagglutinin (PHA). Cyt-B is added to the cultures ~44 h later and cells are usually prepared ~28 h later (i.e. at ~72 h after the start of the cultures). MN are scored in BNC and the NDI (or CBPI) is determined as a measure of proliferation. Although much more information can be gained by analysing the above-mentioned additional parameters, the majority of biomonitoring studies focus on MN frequencies in BNC for the detection of a potential genotoxic effect.
Corresponding to the principle of the test, MN detected in BNC are produced in vitro during cell division in the presence of Cyt-B. MN are produced either spontaneously or as a consequence of DNA damage induced in circulating G0-lymphocytes of mutagen-exposed subjects. However, MN can also be produced in vivo and thus already be present in lymphocytes at the start of the cell culture. The presence of micronucleated peripheral blood lymphocytes at the start of the culture requires the formation of MN (spontaneously or as a consequence of induced DNA damage) during cell division in vivo (e.g. in the bone marrow or lymph nodes).
What happens with micronucleated lymphocytes that are present at the start of the lymphocyte culture? It is unlikely that such cells would appear as micronucleated BNC at 72 h of culture and thus contribute to the MN frequency in BNC. They may persist and remain in culture as mononuclear cells (MNC) with MN. However, it is more likely that they are lost from the culture due to apoptosis or degradation in situ (e.g. as a consequence of premature chromosome condensation) (9) (10) (11) . Elimination of micronucleated cells by apoptosis was found in lymphocyte cultures after treatment with inhibitors of microtubules (12) . The data suggested that the elimination of micronucleated cells was probably not triggered by aneuploidy but the presence of MN. Furthermore, in p53-competent cells, a p53-mediated cell cycle checkpoint seems to prevent the proliferation of micronucleated cells (13) . This also reduces the probability of lymphocytes with MN completing nuclear division in vitro and becoming binuclear in the presence of Cyt-B. Cells with MN, which persist without division or divide without becoming binuclear, do not contribute to the MN frequency scored in BNC.
It has been recommended that investigators should include the scoring of MN in MNC as part of the standard CBMN assay protocol (i.e. MNC would be scored at 72 h after the start of the culture) on the premise that such data might provide useful information on chromosomal aberrations that accumulated in vivo in stem cells and circulating lymphocytes (14) . However, at this sample time, it is not possible to unequivocally distinguish between MN produced in vivo and MN produced in vitro.
Some MNC with MN may be cells that divided in vitro and produced an MN before the addition of Cyt-B (15) . A definitive conclusion regarding the in vivo or in vitro origin of induced MN in lymphocytes is only possible when MN in MNC are scored at an early point during lymphocyte culture before cell division is possible (e.g. 24 h after the start of the culture). At this point in time, all MN seen in MNC were already formed in vivo and present in lymphocytes when the blood sample was taken (15, 16) .
One study has been published, which measured MN in uncultured T lymphocytes of railroad transit workers and referents (17) . However, MN frequencies were not increased in lymphocytes of workers and FISH analysis indicated that in both study groups the majority of MN were centromere-positive, indicating that most of the MN contained whole chromosomes (or chromatids). Another study measured MN in the standard CBMN assay (i.e. in binuclear lymphocytes, 72 h after the start of the cultures) as well as in mononuclear lymphocytes 24 h after the start of the cultures (18) . This was a study of patients who received a cytostatic therapy with high doses of known mutagenic drugs. The results indicated that an in vivo exposure to a mutagen mainly leads to the formation of MN during ex vivo proliferation of lymphocytes in the CBMN assay as a consequence of persistent damage. MN frequencies in MNC (i.e. MN produced in vivo) were only slightly increased in these patients (18) .
In summary, MN may be produced in vivo and appear in MNC in cultured lymphocytes. However, they will not significantly contribute to MN frequencies measured in BNC. MN in BNC are mainly (if not only) produced in vitro, either spontaneously or as a consequence of DNA damage, which was induced in lymphocytes in vivo.
Is the standard protocol of the CBmn assay sensitive enough to detect the genotoxic effects of exposure to environmental and occupational chemicals in human biomonitoring?
Besides its use in human biomonitoring, the CBMN assay with human lymphocytes is primarily used as an in vitro test in genotoxicity testing. A comparison of the protocols of these two applications with regard to their sensitivity for the detection of genotoxic effects provides useful information for a better assessment of the CBMN assay in human biomonitoring. Figure 1 schematically compares the standard protocols of these two applications. The biomonitoring CBMN assay ( Figure 1A ) starts with lymphocytes that were potentially exposed to genotoxic agents in vivo and thus are expected to exhibit increased levels of DNA damage at the start of the culture. As described above, blood samples or isolated lymphocytes are cultured in the presence of PHA, Cyt-B is added ~44 h after PHA stimulation and BNC are prepared for analysis ~72 h after the start of the cultures. For the use of the CBMN assay in in vitro genotoxicity testing, OECD guideline 487 was approved in 2010 (2) . The standard protocol for the in vitro CBMN blood lymphocyte assay according to the OECD guideline was designed to achieve maximum sensitivity ( Figure 1B) . Lymphocyte cultures are exposed to the test substance at 44-48 h after PHA stimulation and not at the start of the cell culture. Cell cycle synchronisation of stimulated lymphocytes has disappeared after 44 h, proliferating cells in all phases of the cell cycle are exposed and the possibility to repair induced damage before MN are produced is reduced compared with exposure at the start of the culture. Most important, BNC analysed under these conditions have definitively divided once during/after compound exposure in the presence of Cyt-B and MN are scored in cells in interphase after the first mitosis following exposure.
In contrast, DNA repair activity, cell division and loss of damaged cells may occur in the CBMN assay biomonitoring protocol before Cyt-B is added to the culture ( Figure 1A) . Thus, this protocol has two critical consequences, both of which limit the sensitivity of the CBMN assay for human biomonitoring. These are (i) the loss of damaged cells during cell culture before Cyt-B is added and BNC can be produced and (ii) the removal of DNA damage by repair mechanisms before MN can be produced.
Damaged cells are lost before BNC are formed
For the sensitive evaluation of induced cytogenetic effects, the most critical factor is the sampling time in relationship to the time of exposure. For the optimal detection of S-phasedependent clastogenic effects, cells should have passed through S-phase in the presence of DNA damage and effects should be evaluated either at the first mitosis (if scoring metaphase cells for chromosome aberrations) or in the daughter cells resulting from that cell division (if scoring for MN). It is a well-known cytogenetic phenomenon that lymphocytes with induced DNA damage produce aberrations mainly during the first cell cycle. Many aberrations are lethal and aberration frequencies in the absence of a continuing exposure decline with each cell division (19) (20) (21) (22) . This applies particularly to unstable chromosome aberrations, which are also a main cause for the formation of MN. Guidelines for the analysis of chromosome aberrations in cultured cells, therefore, require scoring of aberrations in the first metaphase after exposure (23, 24) . According to the International Programme on Chemical Safety (IPCS) guidelines for the chromosome aberration assay in human biomonitoring, 'the single most important aspect of culturing blood samples for the analysis of chromosomal aberrations in human biomonitoring studies is the harvest time. The maximal frequency of chromosomal aberrations in lymphocytes collected from exposed individuals occurs in first-generation, post exposure metaphase cells. The frequency of chromosomal aberrations (except balanced translocations) is decreased greatly in second generation metaphase cells …' (24) .
However, under the conditions of the standard protocol of the CBMN assay in human biomonitoring, it is not necessarily the first division that is completed in the presence of Cyt-B. In our experience, PHA-stimulated lymphocytes start to enter S-phase after about 24 h (25) and most of the mitogenstimulated lymphocytes have completed three cell cycles in the course of the 72-h culture (26) . This is in agreement with earlier experiments, which also found >60% third division metaphases after 72 h (27) . Because mitotic cell divisions already occur in lymphocyte cultures 40 h after PHA stimulation (18, 27) , some lymphocytes will have completed the first division before Cyt-B is added in the CBMN assay. The time between exposure and the targeted mitosis in the presence of Cyt-B is too long and selection against damaged cells is likely to occur. In this context, it is interesting to note that the IPCS suggested an earlier time for the addition of Cyt-B in the CBMN assay in human biomonitoring: 'The correct timing of Cyt-B addition depends on the cell culture system used. In most situations, addition of Cyt-B at 24 h of cultures assures that cells are blocked in their first division, but later time points (e.g. 44 h) can be used if culture technique with slow lymphocyte growth is used' (24) . Consequently, addition of Cyt-B at 44 h may be appropriate only for slowly growing lymphocyte cultures. However, a significantly delayed proliferation of lymphocytes (e.g. a significantly reduced NDI) from subjects exposed to environmental genotoxins has rarely been reported.
DNA damage is repaired before MN can be produced
Another important shortcoming of the CBMN assay for the detection of genotoxic effects in human populations is that the DNA damage induced in vivo can be repaired in vitro before chromosome aberrations are induced that lead to MN during cell division in the presence of Cyt-B. It is generally assumed that lymphocytes accumulate DNA damage during their lifespan in the human body and that MN in BNC provide a measure of the lesions, which have accumulated since the lymphocytes last replicated in vivo (14) . It has in fact been shown that the duration of exposure to environmental carcinogens may be correlated with DNA adduct levels in human lymphocytes (28) . Associations between increased DNA adduct level in peripheral blood cells and enhanced MN formation in cultured lymphocytes have been reported, for example, in coke-oven workers and in cord blood after maternal exposures to trafficrelated air pollution (29, 30) . However, even the increased adduct levels are rather low (in the range of 1-5 adducts per 10 8 nucleotides) and it is unclear whether they are sufficient for the induction of MN in cultured lymphocytes. A definite proof for a causal relationship between environmental exposures, damage levels in lymphocytes and the induction of MN in the CBMN assay is still missing.
Not much is known about the DNA repair capacity of circulating lymphocytes in vivo, but it is well known from in vitro studies that PHA-stimulated lymphocytes can repair induced DNA damage. The repair mechanisms involved in the removal of lesions induced in vitro should be equally sensitive toward DNA damage induced in vivo. The contribution of the lymphocytes' repair activity to the insensitivity of the CBMN assay for the detection of DNA damage induced by chemicals in humans in vivo was demonstrated as early as 1992. Fenech and Neville (31) stated 'Due to their origin, MN in lymphocytes are also likely to be a relative insensitive indication of in vivo exposure to non-radiomimetic chemicals'. This means that the CBMN assay is likely sensitive for DNA damage induced in vivo by ionising radiation and radiomimetic chemicals (because these mutagens induce DNA double-strand breaks and the formation of chromosome aberrations and MN is not S-phase dependent) but less sensitive for detecting DNA damage induced in vivo by S-phase dependent (non-radiomimetic) mutagens. Because nearly all mutagenic substances in our environment and at the workplace are S-phase dependent (i.e. replication on a damaged DNA template is required to form an aberration), this insensitivity seems to be a general problem of the CBMN assay in human biomonitoring. The impact of DNA repair on the sensitivity of the CBMN assay has also been stressed by Surrallés et al. (32) : 'The cytokinesis block micronucleus assay is relatively insensitive to detect agents that predominantly induce excisionrepairable DNA lesions'. This was confirmed by Andreoli et al. (33) : 'Only a minor fraction of damage induced in resting lymphocytes is available for fixation because of its effective repair prior to S-phase'. In these studies, experiments were performed with various mutagens (including alkylating and oxidising agents) in the absence or presence of the DNA repair inhibitor cytosine arabinoside (ARA-C) during the first 16 h of lymphocyte culture. MN induction (scored in BNC) only occurred or was strongly enhanced when repair of induced DNA damage was inhibited (31) (32) (33) . These results clearly show that efficient DNA repair reduces the level of DNA lesions in lymphocytes with increased levels of DNA damage at the start of the culture that would lead to MN formation in the CBMN assay; a phenomenon that also applies to human biomonitoring. Fenech and Kirsch-Volders (6) recently underlined that the proper protocol to detect in vitro excision-repairable DNA lesions with the CBMN assay is to use the ARA-C protocol. However, it is not known whether the use of a modified CBMN assay with ARA-C-inhibited DNA repair would actually improve the sensitivity of the CBMN assay in human biomonitoring. To my knowledge, only one study has used this approach (in vitro ARA-C treatment for the first 16 h of culture), but it failed to demonstrate any significant effect on MN frequencies in BNC using blood cultured from individuals potentially exposed to genotoxic environmental pollutants and/or tobacco smoke (34) . Further research and experience are needed here.
In our recent publication (5), we compared the potential of known mutagens to induce MN in the in vitro CBMN assay after exposure for 2 h either at the beginning of the culture or 42 h later (before the addition of Cyt-B). The first protocol resembles the situation in human biomonitoring except that cells were damaged ex vivo. The second protocol refers to the OECD guideline for the in vitro CBMN assay in genotoxicity testing (2) . Several mutagens, including the alkylating agents methyl methanesulphonate, ethyl methanesulphonate and ethyl nitrosourea, benzopyrene-diol-epoxide, styrene oxide and formaldehyde, did not significantly induce MN in BNC when lymphocytes were exposed at the start of the culture (5, 25) . DNA damage was clearly induced in these cultures (as shown by increased DNA migration in the comet assay performed in parallel and the distribution of damage across cells) (7) and lymphocytes proliferated well (as indicated by the NDI), but MN frequencies in BNC were not significantly induced. In contrast, under the standard conditions of the in vitro CBMN assay, these mutagens clearly induced MN (5, 25) . The relative insensitivity of the CBMN assay for the detection of excision-repairable DNA lesions present at the start of the lymphocyte culture is also supported by results from previous publications (32, 33) . Interestingly, mitomycin C (MMC) was the only tested mutagen in our recent study that clearly induced MN when added at the beginning of the lymphocyte culture (5) . MN induction by MMC was not enhanced by repair inhibitors (32) . It can be assumed that DNA-DNA crosslinks as induced by MMC represent a type of DNA damage that is not efficiently repaired in lymphocytes and may persist until MN are produced in the presence of Cyt-B. However, efficient DNA-DNA crosslinkers are extraordinarily rare among environmental mutagens. They are frequently used in cytostatic therapies and may contribute to positive CBMN assay results in cancer patients after chemotherapy (18, 35) . The comparison of the two protocols indicates that the CBMN assay as used in human biomonitoring is much less sensitive than the in vitro CBMN assay used in genotoxicity testing. However, even using the sensitive protocol of the in vitro CBMN assay, relatively high mutagen concentrations (i.e. damage levels) are needed to induce MN (5). These results suggest that the CBMN assay as such cannot be regarded as a sensitive genotoxicity test (in terms of detecting low levels of DNA damage) and the protocol used in human biomonitoring is particularly insensitive. With the exception of high exposure toward mutagens inducing poorly repairable lesions, positive results cannot be expected with this protocol.
Although the comparability of exposure in vitro versus in vivo may be assessed controversially (6, 7) , the plausible assumption is that the types of DNA damage induced in vivo and in vitro are the same, that potential accumulation of DNA damage in vivo does not lead to higher damage levels than achieved by in vitro exposure and that DNA repair in vitro eliminates damage induced in vivo or in vitro to a similar extent. Therefore, despite the fact that the available data are rather limited and some remaining uncertainties with regard to the direct comparability of in vitro and in vivo results, there is good reason for a critical reappraisal of the CBMN assay in human biomonitoring and the identification of research needs.
In summary, the CBMN assay as generally used in human biomonitoring (i.e. measurement of MN frequencies in BNC) is an insensitive test because not all effects are evaluated in cells after the first division in vitro and damaged cells are lost before the formation of BNC. Furthermore, induced DNA damage is efficiently repaired before a MN can be produced. Due to this insensitivity, it is highly unlikely that DNA damage induced by exposures toward environmental and occupational chemicals in vivo leads to increased MN frequencies in BNC. Increased MN frequencies can only be expected after exposure to ionising radiation and radiomimetic chemicals or after very high exposure to chemical mutagens producing persistent DNA lesions (as used in cancer therapy).
Conclusions
The principle of the CBMN assay and available data suggest that MN scored in BNC are mainly formed in vitro as a consequence of DNA damage present in the lymphocytes of the subjects investigated. MN already produced in vivo do not substantially contribute to the MN frequency measured in BNC. Loss of damaged cells during cell culture before Cyt-B is added and removal of damage by DNA repair mechanisms before MN can be produced reduce the sensitivity of the assay. A comparison with the in vitro CBMN assay shows that the protocol of the CBMN assay used in human biomonitoring is rather insensitive. Reported associations between exposures toward chemicals at concentrations present at the workplace or in the environment and effects in the CBMN assay cannot readily be explained by DNA damage induced in vivo. Based on these considerations, this commentary casts fundamental doubt on the plausibility and reliability of many positive results obtained and questions their relevance in hazard identification and risk assessment. It seems to be worthwhile to reconsider the use of the CBMN assay for the detection of genotoxic exposures in human biomonitoring. 
